Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Exp Clin Endocrinol Diabetes ; 125(3): 156-162, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27657997

ABSTRACT

Background: Adipolin, the novel adipokine that is proposed to be reduced in diabetes, obesity and inflammation, may improve glycemic control. It is known that coenzyme Q10 could improve insulin sensitivity. The aim of the current study was to investigate the effect of Q10 supplementation on adipolin concentration and glucose metabolism in overweight and obese diabetic patients. Material & Methods: Sixty four patients with type 2 diabetes and 25

Subject(s)
Adipokines/blood , Diabetes Mellitus, Type 2 , Obesity , Ubiquinone/analogs & derivatives , Adult , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Female , Glycated Hemoglobin/metabolism , Humans , Male , Middle Aged , Obesity/blood , Obesity/diet therapy , Ubiquinone/administration & dosage
2.
Minerva Endocrinol ; 40(4): 259-66, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26140473

ABSTRACT

AIM: According to many studies, supplementation with Coenzyme Q10 (CoQ10) yields beneficial results in terms of endothelial function in type 2 diabetes mellitus. Despite these promising results, data elucidating the effect of CoQ10 on plasma levels of asymmetric dimethylarginine (ADMA), as a recently discussed cardiovascular risk factor, is lacking. This study was designed to investigate the effect of CoQ10 supplementation on endothelial function, specifically by evaluating plasma ADMA levels. METHODS: Sixty-four type 2 diabetic patients were randomly assigned to two groups; either receiving 200mg/d oral dose of CoQ10 (N.=31) or receiving placebo (N.=33) for 12 weeks. Clinical and biochemical assessments were performed before and after the trial for evaluating ADMA, serum nitrite and nitrate (NOx), hemoglobin A1c and lipid profile. RESULTS: The intervention resulted in a significant improvement in ADMA, NOx , low-density lipoprotein and hemoglobin A1c levels in CoQ10 compared to placebo group. Interestingly, difference in changes of these parameters were also significant (P=0.01, 0.03, 0.04 and 0.03, respectively). CONCLUSION: Supplementation with CoQ10 yields beneficial effects on ADMA levels, leading to decreased diabetic cardiovascular events.


Subject(s)
Antioxidants/therapeutic use , Arginine/analogs & derivatives , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Ubiquinone/analogs & derivatives , Adult , Aged , Arginine/blood , Blood Glucose/analysis , Dietary Supplements , Double-Blind Method , Female , Glycated Hemoglobin/analysis , Humans , Male , Middle Aged , Ubiquinone/therapeutic use
3.
Minerva Gastroenterol Dietol ; 59(2): 231-6, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23831913

ABSTRACT

AIM: Increased oxidative stress and impaired antioxidant defense contribute to pathogenesis and progression of type 2 diabetes. Consistent with this fact, it has been shown that diabetic patients have reduced coenzyme Q10 level. In this study we sought to compare the effect of coenzyme Q10 versus placebo on glycemic control and lipid profile in type 2 diabetic patients. METHODS: In a randomized double-blind placebo-controlled trial, 64 type 2 diabetic patients were randomly assigned to receive either 200 mg Q10 or placebo daily for 12 weeks. Fasting blood samples were obtained and fasting plasma glucose (FPG), HbA1c, total cholesterol (TC), triglycerides (TG), LDL-C and HDL-C were measured. RESULTS: In this study no significant differences considering age, body mass index (BMI), diabetes duration, FPG, HbA1c, TC, TG, LDL-C and HDL-C were shown between two groups. Serum HbA1C concentration decreased in the Q10 treated group (8 ± 2.28 vs. 8.61 ± 2.47%) with no significant effect in the placebo group. Following intervention no differences have been shown regarding FPG, TG and HDL-C in Q10 treated group. Furthermore, mean differences of TC and LDL-C level were statistically altered between two groups (P value=0.027 and 0.039 respectively). CONCLUSION: In this study, Q10 treatment improved glycemic control, total and LDL cholesterol but these differences were associated with no favourable effects on TG and HDL-C.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Ubiquinone/analogs & derivatives , Double-Blind Method , Female , Humans , Male , Middle Aged , Ubiquinone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...